At the end of the day, weight loss options, like any other health-related decisions, are very personal and must be made on a ...

This voluntary consensus standard outlines best practices for hazard communication, regulatory compliance, and training.

After just a few years on the market, a new wave of GLP-1 drugs approved for weight loss have upended what we know about obesity. By now, these are household names: Mounjaro. Wegovy. Zepbound ...

Vocational Education and Training (VET) offers different level courses so you can choose the skill level you need. For example: VET courses give you skills that are relevant. They are designed to meet ...

Josh Gad is opening up about the weight loss success he’s had with GLP-1 medication — and sharing some of the conflicted feelings he’s had along the way. “I’m on a GLP-1 … this is the ...

WASHINGTON (AP) — President Donald Trump signed a flurry of executive orders focused on the military Monday evening, including to reinstate troops booted for refusing COVID-19 vaccines, assess ...

Unfortunately, many patients may choose to forego additional treatments due to the dramatic increase in cost associated with brand name versus compounded GLP-1 drugs. 5. Q. Are any GLP-1s still on ...

“Our study confirms the increased likelihood of being diagnosed with what appears to be low-risk thyroid cancer after treatment with GLP-1 RAs — but not because patients treated with GLP-1 RAs ...

In a meta-analysis of nine randomized controlled trials, adults had an average lean mass loss of 2.5 kg with GLP-1 therapy. More research is needed to examine the implications of lean mass loss ...

The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class of drugs called glucagon-like peptide-1 agonists, or GLP-1.

Oprah Winfrey says taking a GLP-1 drug such as Ozempic and Wegovy has changed her entire perspective on “thin people.” A Type 2 diabetes medication that can also aid in weight loss ...

A study of more than two million people with diabetes builds on evidence of broad-ranging benefits and risks of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in the clinical setting ...